About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Oral Nadolol for the Treatment of Adults With Mild Asthma

NCT00670267·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Invion, Inc.

With

University of Houston
Sandler Program for Asthma Research
Baylor College of Medicine

Age

18–60

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Pre-bronchodilator FEV1 80% or greater than the predicted value.
PC20 FEV1 ≤4 mg/ml on methacholine challenge test.
Blood Pressure ≥ 100/65mm Hg.
Pulse rate ≥ 60 beats/min.
No significant health issues.
Non-smoker or X-smoker \< 10 pack/year.

You may not be if

History of upper/lower respiratory tract infection or asthma exacerbation within 6 weeks of first baseline visit.
Currently diagnosed with chronic obstructive pulmonary disease (COPD).
Used any oral or inhaled corticosteroids within 4 weeks of the first baseline visit.

The record

StatusCompleted

PhasePhase 1–2

Taking part10

StartedJan 2007

UpdatedMay 11, 2016

Conditions

Where1

Baylor College of Medicine
Houston, Texas, United States

Clareo Health | Oral Nadolol for the Treatment of Adults With Mild Asthma